Piper Jaffray analyst William Quirk raised his price target for Accelerate Diagnostics to $22 after the company reported Q4 revenue inline with its preannouncement. The analyst continues to believe the reagent rental shift is the correct market approach for Pheno, and looks forward to increasing placements in the coming quarters. He keeps an Overweight rating on Accelerate Diagnostics.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.